Today: 9 July 2026
Browse Category

Earnings Reports 4 November 2025 - 5 November 2025

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings reportstockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now only a few points shy of its 52-week peak of $43.72investing.com.
5 November 2025
··
Babcock & Wilcox (BW) Stock Skyrockets on AI Power Deal – Key Facts, Q3 Earnings & 2025 Outlook

Babcock & Wilcox (BW) Stock Skyrockets on AI Power Deal – Key Facts, Q3 Earnings & 2025 Outlook

Babcock & Wilcox Enterprises, Inc. is an American energy technology and services provider with a 158-year legacy. Headquartered in Akron, Ohio, the company is historically renowned for its steam boilers used in power generation Wikipedia. Today, B&W’s offerings span advanced energy and environmental solutions for industrial and utility markets worldwide Tipranks. It engineers and supplies equipment for power generation, emissions control systems, and related services/parts.
5 November 2025
·····
Trex Stock Plunges on Earnings Miss – What’s Next for the Decking Leader?

Trex Stock Plunges on Earnings Miss – What’s Next for the Decking Leader?

Trex stock has endured a steep slide in 2025, culminating in a dramatic plunge after its early November earnings announcement. On November 5, 2025, TREX opened around $34–35 per share – down roughly 26% from the prior day’s close Streetinsider. This selloff pushed the stock to fresh 52-week lows, shattering the previous low of ~$46 Finviz. Prior to the earnings drop, Trex had already been trending downward for months; with this latest collapse, shares have lost about 50% of their value year-to-date Finviz and over 50% from 12-month highs.
5 November 2025
···
Why Zeta Global (ZETA) Stock Is Soaring: 17 Straight Beats, AI Power, and Big Upside Ahead

Why Zeta Global (ZETA) Stock Is Soaring: 17 Straight Beats, AI Power, and Big Upside Ahead

Zeta Global made headlines on November 4, 2025 by reporting stellar third-quarter results and raising its guidance for the 17th straight quarterinvestors.zetaglobal.com. The Q3 earnings release showed better-than-expected revenue and profits, prompting a surge of optimism from investors and analysts alike. By the next day, ZETA’s stock price had soared roughly 15% in heavy trading as the market digested the newsstockanalysis.com. This marked a sharp positive turnaround, especially considering that just a few months prior the stock was languishing near yearly lows.
5 November 2025
···
DigitalOcean Stock Skyrockets on AI Momentum and Earnings Beat – What’s Next for DOCN?

DigitalOcean Stock Skyrockets on AI Momentum and Earnings Beat – What’s Next for DOCN?

DigitalOcean’s stock has seen dramatic near-term gains on the back of its latest earnings news. The shares closed at $39.11 on Nov. 4, 2025marketbeat.com, then soared roughly 15–17% in pre-market and early trading after the Q3 report to around the mid-$45 rangemarketbeat.com. This post-earnings rally stands out because the stock had been relatively flat in the month prior before optimism built ahead of the reportchartmill.com. On October 31, for example, DOCN jumped over 7% intraday to ~$41 on strong momentum and anticipationmarketsmojo.com.
5 November 2025
····
Pinterest Stock Plunges 18% on Earnings Miss – Can AI and Record Users Fuel a Rebound?

Pinterest Stock Plunges 18% on Earnings Miss – Can AI and Record Users Fuel a Rebound?

Pinterest stock tumbled after its latest earnings release, with shares sinking 18% on Nov. 5 as the company’s weak holiday-quarter outlook spooked investorsinvesting.com. The steep drop – the stock’s worst single-day slide in years – came despite strong user growth and solid revenue gains. Pinterest’s management forecast Q4 revenue of $1.31–1.34 billion, slightly below Wall Street’s ~$1.34B consensus at the midpoint, fueling fears of slowing momentuminvesting.com. This dour guidance, combined with an earnings miss, sparked a broad selloff.
5 November 2025
··
Super Micro’s AI Server Boom: SMCI Stock Stumbles on Earnings Miss but Preps for a Major Rebound

Super Micro’s AI Server Boom: SMCI Stock Stumbles on Earnings Miss but Preps for a Major Rebound

Super Micro’s latest earnings report initially shocked investors, sending the stock down over 8–9% in after-hours and pre-market trading Reuters Alphaspread. The company missed Wall Street’s expectations on both the top and bottom lines. Revenue for the September quarter came in at $5.0 billion, well under the ~$5.8–6.0B analysts had anticipated Finanznachrichten. This was a 15.5% drop from the $5.94B in the same quarter last year Finanznachrichten – a rare year-over-year decline for a high-growth tech company. Net income plunged accordingly; GAAP earnings were just $0.26 per share Finanznachrichten. On an adjusted basis, EPS was $0.35, missing consensus by roughly 10–25% Finanznachrichten Marketbeat.
5 November 2025
····
Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quartersinvesting.com, marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY to $4.48 Binvesting.com, while adjusted earnings jumped to $0.78 per sharereuters.com. Notably, this beat Wall Street estimates by ~$0.10 and marked Teva’s strongest earnings surprise of 2025reuters.com. The growth engines are Teva’s newer branded drugs: movement-disorder treatment Austedo, migraine injection Ajovy, and schizophrenia depot UZEDY. Together these “innovative medicines” climbed 33% YoY and contributed $830 M this quarterinvesting.com, helping offset flat-to-declining sales in older generic categories. “Our key innovative brands…delivered a 33% increase…underscoring their impact on both patient outcomes and our financial performance,” CEO Richard Francis notedtevapharm.comtevapharm.com. Importantly, Austedo’s momentum led management to raise Austedo’s 2025 revenue outlook to $2.05–$2.15 Binvesting.com. This bodes well for continued earnings expansion, since these specialty products carry higher margins than commodity generics.
5 November 2025
···
Axon Enterprise (AXON) Stock Plunges on Earnings Miss – What’s Next for the Taser Maker?

Axon Enterprise (AXON) Stock Plunges on Earnings Miss – What’s Next for the Taser Maker?

Axon’s stock has experienced whiplash in early November. After closing at $706.13 on Nov 4stockanalysis.com, shares tumbled to around $563 in pre-market trading the next daystockanalysis.com. This ~20% drop followed the company’s Q3 earnings announcement, where profits disappointed Wall Street. In fact, Axon’s stock had already been sliding for several days heading into the report – falling four days in a row from about $732 at the end of October to $706 on Nov 4stockinvest.us.
5 November 2025
···
Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis

Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis

In summary, Humana Inc. faces a pivotal moment: it’s balancing short-term earnings headwinds from elevated costs and rating setbacks against strong long-term fundamentals in the Medicare Advantage space. The latest news provides some relief that management’s corrective actions are workingreuters.comreuters.com. However, caution prevails as 2026 looms without guidance and with likely flat profitsreuters.com. Investors should watch upcoming quarters for signs of cost trend stabilization, membership retention during open enrollment, and progress on quality metrics. Humana’s ability to navigate these challenges under new leadership will determine if the stock can regain its former strength. For now, the consensus is that Humana will weather the storm: it remains a market leader in a growing sector, with a strategy to adapt and thrive. As one analyst succinctly put it, “Humana’s crown slipped, but it’s far from lost.” The coming year will show how quickly that crown can be polished again.
5 November 2025
··
Lemonade (LMND) Stock Soars on Q3 Beat – Is Insurtech Growth Sustainable?

Lemonade (LMND) Stock Soars on Q3 Beat – Is Insurtech Growth Sustainable?

On Nov. 5, 2025 after market-close, Lemonade released its Q3 financials, and the stock surged. Both press coverage and company statements highlighted robust top-line growth and improving loss metrics. For example, Investing.com reported revenue +42% YOY to $194.5M and a narrower-than-forecast loss of $0.51 per shareau.investing.com. It noted in-force premium up 30% YOY to $1.16B – an eighth consecutive quarter of accelerating growthau.investing.com. The CEO, Daniel Schreiber, said: “In Q3, we continued both our growth acceleration — crossing 30% IFP growth ahead of schedule — and our steady progress toward profitability.”investorshub.advfn.com.
5 November 2025
··
Zeta Global (ZETA) – 17th Straight Beat & Raise Quarter Ignites AI-Cloud Rally – Analysts Eye ~$28 Target (≈+70% Upside)

Zeta Global (ZETA) – 17th Straight Beat & Raise Quarter Ignites AI-Cloud Rally – Analysts Eye ~$28 Target (≈+70% Upside)

Zeta’s stock has trended down from its late-2024 highs as broader growth-tech valuation pressures emerged. At the Nov 4 close, ZETA was ~$16.70stockanalysis.com, near its 52-week low and well below its peak. Over the year it’s down ~–7%marketbeat.com, while smaller tech peers have also lagged. On Nov 4 its volume was ~11.2 M sharesstockanalysis.com, reflecting heavy trading after earnings.
4 November 2025
··
Rivian Slashes 600 Jobs as EV Demand Slumps – Stock Hits & Experts Sound Alarm

Rivian Rally or Risk? EV Start-up Stock Jumps on Q3 Beat, Layoffs & R2 Hype

Key Facts: Rivian’s stock closed around $13 on Nov. 4, 2025, giving it a market cap of about $15.2 billionstockanalysis.com. In Q3 2025 Rivian delivered 13,201 vehicles and reported $1.558 billion in revenue, up 78% year-over-yearbusinesswire.com. Adjusted gross profit turned positive for the quarterbusinesswire.com. Management kept 2025 delivery guidance at 41,500–43,500 vehiclesbusinesswire.com; losing the $7,500 federal EV tax credit caused a short-term pull-forward of orders, then softer demandreuters.comreuters.com. Rivian announced a 600‑job layoff on Oct. 23 to cut costsreuters.com. CEO RJ Scaringe said the company is on track to start production of its new R2 mid‑size SUV in H1 2026businesswire.comtechbuzz.ai. Analysts currently have a “Hold/Reduce” consensus on RIVN, with an average 12‑month target near $13–14marketbeat.commarketbeat.com. Wall Street price targets range from about $10 to $21marketbeat.commarketbeat.com, reflecting wide views on Rivian’s outlook.
4 November 2025
···
Axon Stock Rockets 420% Overseas as Wall Street Targets $1,000 – Should You Buy the Dip?

Axon Enterprise Rockets Past Revenue Goals – But EPS Miss Sends Stock Reeling

Axon’s Q3 results beat revenue expectations but showed a small profit shortfall. The company “delivered another record quarter, with revenue growing 31% year over year to $711 million”prnewswire.com, marking its seventh straight quarter above 30% growth. Sales growth was driven by the software business – Axon’s Software & Services segment grew 41% to $305Mprnewswire.com – as well as by strong demand for Tasers and body cameras. On the profitability side, Axon reported a tiny GAAP net loss of just $2.0Mprnewswire.com, largely due to investment in staff and R&D. By contrast, non-GAAP net income was $98M. Adjusted EBITDA of $177M was up 22% year-over-yeargurufocus.com.
4 November 2025
··
Reddit’s Stock Explodes! 78% Revenue Surge, Google AI Deal Talks & 70% Rally 🔥

Reddit’s Stock Soars on Blowout Earnings – 7 Must-Know Facts for Investors

In early November 2025, Reddit Inc. is making headlines for its stellar third-quarter performance and the market’s reaction to it. The company announced Q3 2025 results on October 30, delivering growth figures that impressed investors and analysts alike. Reddit’s revenue for the quarter jumped 68% year-over-year to $585 million, well above consensus estimatesmarketbeat.com. Net income came in at $163 million, handily beating forecasts of about $0.50 and marking a huge increase from the $0.16 EPS in the same quarter last yearmarketbeat.com. These blowout results immediately boosted market confidence – Reddit’s stock rose sharply in the days following the earnings release, at one point climbing over 7% as investors digested the newstechbuzz.aibarchart.com.
4 November 2025
···
Xometry (XMTR) Stock Soars on Record Q3 Earnings – What’s Next for This AI Manufacturing Marketplace?

Xometry (XMTR) Stock Soars on Record Q3 Earnings – What’s Next for This AI Manufacturing Marketplace?

Xometry’s stock has been on a tear in early November 2025. On Nov 4, 2025, shares skyrocketed ~24% intraday following the Q3 earnings announcement, peaking around $60 and nearing a 52-week high of $60.68ainvest.com. It closed the day at roughly $60.23investing.com. This record high represents a dramatic one-day gain and continues a strong upward trend – the stock has more than tripled from its 52-week low of ~$18.59 earlier in the yearinvesting.com.
4 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week rangemarketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s following its government pricing deal announcementmarketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However, disappointing industry news and the uncertainty of the Metsera takeover battle led to profit-taking. By early November, Pfizer’s 50-day average converged with its 200-day averagemarketbeat.com, indicating a lack of a strong trend. This technical “flatline” suggests the stock is searching for direction, consolidating after its volatile swings.
4 November 2025
·····
Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis stock traded in the mid-$80s in early November 2025, rallying on earnings news. It closed around $86.24 on Nov 4, 2025, up about 5% for the day and roughly 8–9% over the two sessions surrounding its earnings report. This rebound comes after a soft October where ACLS had slid ~14% over a monthnasdaq.com, underperforming the tech sector. Even after the post-earnings pop, shares remain well below their 52-week high of ~$103 and about double the 52-week low near $40marketbeat.com, reflecting both the stock’s volatility and longer-term growth.
4 November 2025
····
1 … 247 248 249 250 251 … 261

Stock Market Today

  • Hong Kong Small IPOs Struggle as Big Names Like Zhipu AI Draw Focus
    July 9, 2026, 5:50 AM EDT. Hong Kong's IPO market is cold for small-caps, with liquidity tight and investors chasing bigger deals like Zhipu AI. Out of 13 fresh listings, five opened under water, among them Apple supplier Luxshare, down over 9% at the debut. Rigol Technologies and Beijing TRT Healthcare sank more than 30%. Only Qiyunshan Food managed to double. Yongkang Holdings scrapped its July 13 IPO, even after retail orders were oversubscribed. UOB Kay Hian's Steven Leung said AI stocks raising money are under pressure as lock-ups expire and Asia-US market weakness continues. Profit-taking in AI names is dampening new deal appetite, leaving smaller floats exposed.
Go toTop